Literature DB >> 27036055

Cordyceps sinensis Oral Liquid Inhibits Damage Induced by Oxygen and Glucose Deprivation in SH-SY5Y Cells.

Ying-Xin Zou, Yu-Xiang Liu, Ming-Hua Ruan, Yi Zhou, Jia-Chun Wang, Zhi-Yong Chu.   

Abstract

CONTEXT: Cordyceps sinensis has been used in traditional Chinese medicine for thousands of years. It has been demonstrated to have a variety of biological activities, and an extract of it has been demonstrated to possess a protective effect in occlusion-induced focal cerebral ischemia of the middle cerebral artery in rats. It could be explored as an agent for treatment of ischemic stroke, and the mechanisms need to be studied further.
OBJECTIVE: The study intended to investigate the protective effects of the Cordyceps sinensis oral liquid (CSOL) against damage induced by oxygen and glucose deprivation (OGD) in SH-SY5Y cells. DESIGN • The research team designed an in vitro study.
SETTING: The study occurred at the Naval Medical Research Institute in Shanghai, China. INTERVENTION: SH-SY5Y cells were exposed to CSOL in doses of 0.01, 0.03, 0.10, 0.30, and 1.00 mg/mL, creating 5 intervention groups. The OGD condition was induced by transfer of the cells from high-glucose Dulbecco's Modified Eagle's medium (DMEM) in a box gassed with air containing 5% CO2 to glucose-free DMEM in a box gassed with 94% N2, 5% CO2, and 1% O2. Like the cells for the interventions groups, the cells for a model group were cultured with high-glucose DMEM and were transferred to the OGD, but they received no dose of COSL. Cells in a control group were cultured with high-glucose DMEM, were not transferred to the OGD condition, and did not receive any dose of COSL. OUTCOME MEASURES: Cell viability was assayed using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) method. The apoptosis and the mitochondrial membrane potential (MMP) were detected by flow cytometry, and the protein expression of caspase-3 was observed by western blot.
RESULTS: After exposure to OGD, the cell viability of cells treated with 0.01, 0.03, 0.10, 0.30, and 1.00 mg/mL of CSOL increased in a dose-effect relationship. Compared with the cells in the model group, the treatment of CSOL at all the experimental concentrations significantly inhibited both the cell apoptosis (P < .01) and the capase-3 activation (P < .01). The MMP dissipation in the cells of the model group increased significantly compared with those of the control group (P < .01). The treatment with all doses of CSOL significantly inhibited the MMP dissipation (P < .01).
CONCLUSIONS: CSOL protects against the damage induced by OGD through inhibiting the mitochondrial apoptosis pathway in SH-SY5Y cells.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27036055

Source DB:  PubMed          Journal:  Altern Ther Health Med        ISSN: 1078-6791            Impact factor:   1.305


  3 in total

1.  Luminescent Human iPSC-Derived Neurospheroids Enable Modeling of Neurotoxicity After Oxygen-glucose Deprivation.

Authors:  Elise Van Breedam; Aleksandra Nijak; Tamariche Buyle-Huybrecht; Julia Di Stefano; Marlies Boeren; Jonas Govaerts; Alessandra Quarta; Tine Swartenbroekx; Eva Z Jacobs; Björn Menten; Rik Gijsbers; Peter Delputte; Maaike Alaerts; Behrouz Hassannia; Bart Loeys; Zwi Berneman; Jean-Pierre Timmermans; Philippe G Jorens; Tom Vanden Berghe; Erik Fransen; An Wouters; Winnok H De Vos; Peter Ponsaerts
Journal:  Neurotherapeutics       Date:  2022-03-14       Impact factor: 6.088

2.  Cordyceps sinensis may inhibit Th22 cell chemotaxis to improve kidney function in lgA nephropathy.

Authors:  Chenggen Xiao; Ping Xiao; Xiaogang Li; Xiaozhao Li; Hui Li; Yusa Chen; Yang Wang; Yan Xu; Guoqing Huang; Qiaoling Zhou
Journal:  Am J Transl Res       Date:  2018-03-15       Impact factor: 4.060

Review 3.  Human Ischaemic Cascade Studies Using SH-SY5Y Cells: a Systematic Review and Meta-Analysis.

Authors:  Ye Liu; Emma D Eaton; Taryn E Wills; Sarah K McCann; Ana Antonic; David W Howells
Journal:  Transl Stroke Res       Date:  2018-03-23       Impact factor: 6.829

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.